原发性胆汁性胆管炎与肠道菌群

赵志斌; 廉哲雄

doi:10.12449/JCH250706

原发性胆汁性胆管炎与肠道菌群

DOI: 10.12449/JCH250706

赵志斌,
廉哲雄^, ,

南方医科大学附属广东省人民医院，广州 510080

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：赵志斌负责撰写初稿；廉哲雄负责指导文章方向及最后定稿。

详细信息

通信作者:
廉哲雄， zxlian@gdph.org.cn （ORCID： 0000-0002-9525-1421）

计量
- 文章访问数: 509
- HTML全文浏览量: 195
- PDF下载量: 176
- 被引次数: 0
出版历程
- 收稿日期: 2025-04-21
- 录用日期: 2025-05-20
- 出版日期: 2025-07-25

Primary biliary cholangitis and the gut microbiome

Zhibin ZHAO,
Zhexiong LIAN^{,
,}

Guangdong Provincial People’s Hospital，Southern Medical University，Guangzhou 510080，China

More Information

Corresponding author: LIAN Zhexiong， zxlian@gdph.org.cn （ORCID： 0000-0002-9525-1421）

摘要

摘要: 近年来，越来越多的研究表明，肠道菌群紊乱在原发性胆汁性胆管炎（PBC）的发病机制中发挥关键作用。肠道菌群通过调节胆汁酸代谢、影响免疫系统功能以及介导“肠-肝轴”的相互作用，参与PBC的发生与发展。本文从PBC的病理生理特征出发，阐述肠道菌群在PBC中的作用机制，并分析基于肠道菌群调节的潜在治疗策略，以期为PBC的早期诊断和精准治疗提供新的理论依据。
- 原发性胆汁性胆管炎 /
- 肠道微生物组 /
- 胆汁酸类和盐类 /
- 免疫系统
Abstract: In recent years， an increasing amount of evidence has shown that intestinal flora disturbance plays a critical role in the pathogenesis of primary biliary cholangitis （PBC）. Intestinal flora participates in the development and progression of PBC by modulating bile acid metabolism， affecting immune system functions， and mediating interactions within the gut-liver axis. This article summarizes the pathophysiological features of PBC， elaborates on the mechanism of action of intestinal flora in PBC， and analyzes the potential treatment strategies based on intestinal flora regulation， in order to provide new theoretical bases for the early diagnosis and precise treatment of PBC.
- Primary Biliary Cholangitis /
- Gastrointestinal Microbiome /
- Bile Acids and Salts /
- Immune System

HTML全文

参考文献(41)

[1]	RONCA V, DAVIES SP, OO YH, et al. The immunological landscape of primary biliary cholangitis: Mechanisms and therapeutic prospects[J]. Hepatology, 2025. DOI: 10.1097/HEP.0000000000001225.[ Epub ahead of print]
[2]	GULAMHUSEIN AF, HIRSCHFIELD GM. Primary biliary cholangitis: Pathogenesis and therapeutic opportunities[J]. Nat Rev Gastroenterol Hepatol, 2020, 17( 2): 93- 110. DOI: 10.1038/s41575-019-0226-7.
[3]	DEVARBHAVI H, ASRANI SK, ARAB JP, et al. Global burden of liver disease: 2023 update[J]. J Hepatol, 2023, 79( 2): 516- 537. DOI: 10.1016/j.jhep.2023.03.017.
[4]	MINEMURA M, SHIMIZU Y. Gut microbiota and liver diseases[J]. World J Gastroenterol, 2015, 21( 6): 1691- 1702. DOI: 10.3748/wjg.v21.i6.1691.
[5]	ZHANG L, YANG L, CHU HK. Targeting gut microbiota for the treatment of primary biliary cholangitis: From bench to bedside[J]. J Clin Transl Hepatol, 2023, 11( 4): 958- 966. DOI: 10.14218/JCTH.2022.00408.
[6]	GUO ZQ, HE K, PANG K, et al. Exploring advanced therapies for primary biliary cholangitis: Insights from the gut microbiota-bile acid-immunity network[J]. Int J Mol Sci, 2024, 25( 8): 4321. DOI: 10.3390/ijms25084321.
[7]	TANG RQ, WEI YR, LI YM, et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy[J]. Gut, 2018, 67( 3): 534- 541. DOI: 10.1136/gutjnl-2016-313332.
[8]	ZHOU YJ, YING GX, DONG SL, et al. Gut microbial profile of treatment-naive patients with primary biliary cholangitis[J]. Front Immunol, 2023, 14: 1126117. DOI: 10.3389/fimmu.2023.1126117.
[9]	MARTINEZ-GILI L, PECHLIVANIS A, MCDONALD JAK, et al. Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis[J]. Gut Microbes, 2023, 15( 1): 2208501. DOI: 10.1080/19490976.2023.2208501.
[10]	LIU QY, HUANG BY, ZHOU YJ, et al. Gut microbiome pattern impacts treatment response in primary biliary cholangitis[J]. Med, 2025, 6( 1): 100504. DOI: 10.1016/j.medj.2024.08.003.
[11]	JIANG HY, YU Y, HU XX, et al. The fecal microbiota of patients with primary biliary cholangitis(PBC) causes PBC-like liver lesions in mice and exacerbates liver damage in a mouse model of PBC[J]. Gut Microbes, 2024, 16( 1): 2383353. DOI: 10.1080/19490976.2024.2383353.
[12]	MA HD, ZHAO ZB, MA WT, et al. Gut microbiota translocation promotes autoimmune cholangitis[J]. J Autoimmun, 2018, 95: 47- 57. DOI: 10.1016/j.jaut.2018.09.010.
[13]	HUANG MX, YANG SY, LUO PY, et al. Gut microbiota contributes to sexual dimorphism in murine autoimmune cholangitis[J]. J Leukoc Biol, 2021, 110( 6): 1121- 1130. DOI: 10.1002/JLB.3MA0321-037R.
[14]	SCHRUMPF E, KUMMEN M, VALESTRAND L, et al. The gut microbiota contributes to a mouse model of spontaneous bile duct inflammation[J]. J Hepatol, 2017, 66( 2): 382- 389. DOI: 10.1016/j.jhep.2016.09.020.
[15]	SHI QM, YUAN X, ZENG YF, et al. Crosstalk between gut microbiota and bile acids in cholestatic liver disease[J]. Nutrients, 2023, 15( 10): 2411. DOI: 10.3390/nu15102411.
[16]	SCHNEIDER KM, CANDELS LS, HOV JR, et al. Gut microbiota depletion exacerbates cholestatic liver injury via loss of FXR signalling[J]. Nat Metab, 2021, 3( 9): 1228- 1241. DOI: 10.1038/s42255-021-00452-1.
[17]	CHEN WH, WEI YR, XIONG AZ, et al. Comprehensive analysis of serum and fecal bile acid profiles and interaction with gut microbiota in primary biliary cholangitis[J]. Clin Rev Allergy Immunol, 2020, 58( 1): 25- 38. DOI: 10.1007/s12016-019-08731-2.
[18]	LI Z, LIU Y, YANG F, et al. Dysregulation of circulating FGF19 and bile acids in primary biliary cholangitis-autoimmune hepatitis overlap syndrome[J]. Biomed Res Int, 2020, 2020: 1934541. DOI: 10.1155/2020/1934541.
[19]	AKEPATI PR, GOCHANOUR EM. Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis[J]. Expert Opin Investig Drugs, 2024, 33( 6): 627- 638. DOI: 10.1080/13543784.2024.2348743.
[20]	WAHLSTRÖM A, SAYIN SI, MARSCHALL HU, et al. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism[J]. Cell Metab, 2016, 24( 1): 41- 50. DOI: 10.1016/j.cmet.2016.05.005.
[21]	ABENAVOLI L, SCARLATA GG, SCARPELLINI E, et al. Therapeutic success in primary biliary cholangitis and gut microbiota: A safe highway?[J]. Minerva Gastroenterol(Torino), 2024, 70( 4): 430- 441. DOI: 10.23736/S2724-5985.23.03590-8.
[22]	ROJAS M, RESTREPO-JIMÉNEZ P, MONSALVE DM, et al. Molecular mimicry and autoimmunity[J]. J Autoimmun, 2018, 95: 100- 123. DOI: 10.1016/j.jaut.2018.10.012.
[23]	TANAKA A, MA X, TAKAHASHI A, et al. Primary biliary cholangitis[J]. Lancet, 2024, 404( 10457): 1053- 1066. DOI: 10.1016/S0140-6736(24)01303-5.
[24]	HOWEL D, FISCHBACHER CM, BHOPAL RS, et al. An exploratory population-based case-control study of primary biliary cirrhosis[J]. Hepatology, 2000, 31( 5): 1055- 1060. DOI: 10.1053/he.2000.7050.
[25]	GERSHWIN ME, SELMI C, WORMAN HJ, et al. Risk factors and comorbidities in primary biliary cirrhosis: A controlled interview-based study of 1032 patients[J]. Hepatology, 2005, 42( 5): 1194- 1202. DOI: 10.1002/hep.20907.
[26]	WANG JJ, YANG GX, ZHANG WC, et al. Escherichia coli infection induces autoimmune cholangitis and anti-mitochondrial antibodies in non-obese diabetic(NOD). B6(Idd10/Idd18) mice[J]. Clin Exp Immunol, 2014, 175( 2): 192- 201. DOI: 10.1111/cei.12224.
[27]	YANG Y, CHOI J, CHEN Y, et al. E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants[J]. Hepatology, 2022, 75( 2): 266- 279. DOI: 10.1002/hep.32172.
[28]	FUSSEY SP, ALI ST, GUEST JR, et al. Reactivity of primary biliary cirrhosis sera with Escherichia coli dihydrolipoamide acetyltransferase(E2p): Characterization of the main immunogenic region[J]. Proc Natl Acad Sci USA, 1990, 87( 10): 3987- 3991. DOI: 10.1073/pnas.87.10.3987.
[29]	TANAKA A, LEUNG PC, GERSHWIN ME. Pathogen infections and primary biliary cholangitis[J]. Clin Exp Immunol, 2019, 195( 1): 25- 34. DOI: 10.1111/cei.13198.
[30]	FELD JJ, MEDDINGS J, HEATHCOTE EJ. Abnormal intestinal permeability in primary biliary cirrhosis[J]. Dig Dis Sci, 2006, 51( 9): 1607- 1613. DOI: 10.1007/s10620-006-9544-z.
[31]	SEKI E, de MINICIS S, OSTERREICHER CH, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis[J]. Nat Med, 2007, 13( 11): 1324- 1332. DOI: 10.1038/nm1663.
[32]	ZHAO JM, ZHAO SX, ZHOU GD, et al. Altered biliary epithelial cell and monocyte responses to lipopolysaccharide as a TLR ligand in patients with primary biliary cirrhosis[J]. Scand J Gastroenterol, 2011, 46( 4): 485- 494. DOI: 10.3109/00365521.2010.539624.
[33]	MAO TK, LIAN ZX, SELMI C, et al. Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis[J]. Hepatology, 2005, 42( 4): 802- 808. DOI: 10.1002/hep.20859.
[34]	KRAUTKRAMER KA, FAN J, BÄCKHED F. Gut microbial metabolites as multi-Kingdom intermediates[J]. Nat Rev Microbiol, 2021, 19( 2): 77- 94. DOI: 10.1038/s41579-020-0438-4.
[35]	FURUKAWA M, MORIYA K, NAKAYAMA J, et al. Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis[J]. Hepatol Res, 2020, 50( 7): 840- 852. DOI: 10.1111/hepr.13509.
[36]	LAMMERT C, SHIN AS, XU HP, et al. Short-chain fatty acid and fecal microbiota profiles are linked to fibrosis in primary biliary cholangitis[J]. FEMS Microbiol Lett, 2021, 368( 6): fnab038. DOI: 10.1093/femsle/fnab038.
[37]	WANG R, LI B, HUANG BY, et al. Gut microbiota-derived butyrate induces epigenetic and metabolic reprogramming in myeloid-derived suppressor cells to alleviate primary biliary cholangitis[J]. Gastroenterology, 2024, 167( 4): 733- 749. e 3. DOI: 10.1053/j.gastro.2024.05.014.
[38]	DHIMAN RK, RANA B, AGRAWAL S, et al. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: A randomized, controlled trial[J]. Gastroenterology, 2014, 147( 6): 1327- 1337. e 3. DOI: 10.1053/j.gastro.2014.08.031.
[39]	HVAS CL, DAHL JØRGENSEN SM, JØRGENSEN SP, et al. Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection[J]. Gastroenterology, 2019, 156( 5): 1324- 1332. e 3. DOI: 10.1053/j.gastro.2018.12.019.
[40]	ALLEGRETTI JR, KASSAM Z, CARRELLAS M, et al. Fecal microbiota transplantation in patients with primary sclerosing cholangitis: A pilot clinical trial[J]. Am J Gastroenterol, 2019, 114( 7): 1071- 1079. DOI: 10.14309/ajg.0000000000000115.
[41]	UMEMURA M, HONDA A, YAMASHITA M, et al. High-fat diet modulates bile acid composition and gut microbiota, affecting severe cholangitis and cirrhotic change in murine primary biliary cholangitis[J]. J Autoimmun, 2024, 148: 103287. DOI: 10.1016/j.jaut.2024.103287.